Schall, Brown & Schwartz LLP has filed a federal securities class action lawsuit against Beta Bionics, Inc. on behalf of investors who purchased BBNX shares between July 30, 2025, and February 24, 2026, alleging false and misleading statements about the company's iLet insulin pump.
Why it matters. Investors who purchased Beta Bionics shares during the class period may be eligible for compensation, affecting their financial interests.
SBS brings together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz.
Beta Bionics, Inc. ("Beta Bionics" or "the Company") (NASDAQ: BBNX) common stock
SBS attorneys are responsible for recovering over a billion dollars for violations of securities laws and corporate misfeasance.
Schall, Brown & Schwartz LLP represents investors around the world, specializing in securities class action lawsuits and shareholder rights litigation.
As the truth emerged, the price of Beta Bionics common stock declined
LOS ANGELES, Oct. 8, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP, a national shareholder rights litigation firm, announces that it has filed a federal securities class action on behalf of purchasers of Beta Bionics, Inc. ("Beta Bionics" or "the Company") (NASDAQ: BBNX) com…
BBNX Investor Alert: Schall, Brown & Schwartz LLP Files Class Action Lawsuit Against Beta Bionics, Inc. and Announces Opportunity for Investors to Lead Class Action Lawsuit
